To help you understand what is going on in the drug and pharmaceutical industry and what we expect to happen in the future, our highly experienced Kiplinger Letter team will keep you abreast of the latest developments and forecasts (Get a free issue of The Kiplinger Letter or subscribe). You'll get all the latest news first by subscribing, but we will publish many (but not all) of the forecasts a few days afterward online. Here’s the latest…
At the very least, 2024 will be better than 2023 for the pharma industry. Swiss pharma giant Roche will score the most sales ($55 billion) of any drugmaker next year on the strength of its biologics portfolio, including Ocrevus, a treatment for MS, as well as anti-cancer agent Tecentriq and hemophilia drug Hemlibra.
Johnson & Johnson (JNJ), Merck, AbbVie (ABBV) and Pfizer will exceed $50 billion in sales, too. But Pfizer, the world’s top-selling drugmaker last year, will fall to fifth place due to declining sales for its pandemic-related treatments.
Another notable change: Novo Nordisk will enter the top 10, supplanting GSK (formerly GlaxoSmithKline). Novo Nordisk will boast the two biggest generators of new drug sales, which are both weight loss-related: Wegovy ($4 billion in new sales) and Ozempic ($3 billion).
From just $107.88 $24.99 for Kiplinger Personal Finance
Be a smarter, better informed investor.
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Combined, total sales of the drugs, which both employ the same active ingredient, Semaglutide, will rival those of Keytruda, the world’s best-selling pharmaceutical. Keytruda, a cancer immunotherapy drug manufactured and marketed by Merck, will generate over $25 billion this year.
Beyond Keytruda, Wegovy and Ozempic, other top sellers include Sanofi and Regeneron’s Dupixent, which is used to treat allergic diseases like eczema, asthma and nasal polyps, Eliquis, the Pfizer and Bristol Myers Squibb drug used to prevent blood clots, and Gilead’s Biktarvy, a fixed-dose combination medication for the treatment of HIV and AIDS.
This forecast first appeared in The Kiplinger Letter, which has been running since 1923 and is a collection of concise weekly forecasts on business and economic trends, as well as what to expect from Washington, to help you understand what’s coming up to make the most of your investments and your money. Subscribe to The Kiplinger Letter.
Related Content
-
September Fed Meeting: Live Updates and CommentaryThe September Fed meeting is a key economic event, with Wall Street keyed into what Fed Chair Powell & Co. will do about interest rates.
-
Ask the Editor: Questions on 529 Plan Rollovers to a Roth IRAAsk the Editor In this week's Ask the Editor Q&A, we answer four questions from readers on transferring 529 plan money to a Roth IRA.
-
How AI Puts Company Data at RiskThe Kiplinger Letter Cybersecurity professionals are racing to ward off AI threats while also using AI tools to shore up defenses.
-
AI Start-ups Are Rolling in CashThe Kiplinger Letter Investors are plowing record sums of money into artificial intelligence start-ups. Even as sales grow swiftly, losses are piling up for AI firms.
-
What is AI Worth to the Economy?The Letter Spending on AI is already boosting GDP, but will the massive outlays being poured into the technology deliver faster economic growth in the long run?
-
Kiplinger Special Report: Business Costs for 2026Economic Forecasts Fresh forecasts for 2026, to help you plan ahead and prepare a budget on a range of business costs, from Kiplinger's Letters team.
-
Trump-Era Regulations Will Broaden Access to CryptoThe Kiplinger Letter The president wants to make the U.S. the leader in digital assets.
-
How to Adopt AI and Keep Employees Happy
The Kiplinger Letter As business adoption of AI picks up, employee morale could take a hit. But there are ways to avoid an AI backlash.
-
The Rise of AI: A Kiplinger Special ReportThe Kiplinger Letter Our special report looks at the opportunities and challenges of generative AI and how its rapid move into the mainstream is impacting every aspect of our lives.
-
Big Changes Are Ahead for Higher EdThe Kiplinger Letter A major reform of higher ed is underway. Colleges are bracing for abrupt change, financial headwinds and uncertainty.
